Regulatory Updates From the FDA: Advancing Endpoints & Innovative Trial Design for Chronic Kidney Disease Drug Development

Time: 8:30 am
day: Day One

Details:

  • Evolving surrogate endpoints and assessing accelerated approval programs
  • Identifying opportunities to implement real-world evidence in trial design
  • Progressing patient focused drug development and decentralized trials

Speakers: